Abstract: A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may be substantially free of B2O3, SrO, BaO, and ZrO2.

Abstract: Embodiments of a vehicle interior system are disclosed. In one or more embodiments, the system includes a base with a curved surface, and a display or touch panel disposed on the curved surface. The display includes a cold-bent glass substrate with a thickness of 1.5 mm or less and a first radius of curvature of 20 mm or greater, and a display module and/or touch panel attached to the glass substrate having a second radius of curvature that is within 10% of the first radius of curvature. Methods for forming such systems are also disclosed.

Abstract: Embodiments of a vehicle interior system are disclosed. In one or more embodiments, the system includes a base with a curved surface, and a display or touch panel disposed on the curved surface. The display includes a cold-bent glass substrate with a thickness of 1.5 mm or less and a first radius of curvature of 20 mm or greater, and a display module and/or touch panel attached to the glass substrate having a second radius of curvature that is within 10% of the first radius of curvature. Methods for forming such systems are also disclosed.

Abstract: A method for processing material includes sintering a portion of a sheet of material at a location on the sheet, moving the sintering location along the sheet of material at a first rate, and pulling the sintered material away from the sintering location at a second rate that is greater than the first rate.

Abstract: The embodiments described herein relate to chemically and mechanically durable glass compositions and glass articles formed from the same. In another embodiment, a glass composition may include from about 70 mol. % to about 80 mol. % SiO2; from about 3 mol. % to about 13 mol. % alkaline earth oxide; X mol. % Al2O3; and Y mol. % alkali oxide. The alkali oxide may include Na2O in an amount greater than about 8 mol. %. A ratio of Y:X may be greater than 1 and the glass composition may be free of boron and compounds of boron. In some embodiments, the glass composition may also be free of phosphorous and compounds of phosphorous. Glass articles formed from the glass composition may have at least a class S3 acid resistance according to DIN 12116, at least a class A2 base resistance according to ISO 695, and a type HGA1 hydrolytic resistance according to ISO 720.

Abstract: Embodiments of this disclosure pertain to a strengthened glass article including a first surface and a second surface opposing the first surface defining a thickness (t) of about less than about 1.1 mm, a compressive stress layer extending from the first surface to a depth of compression (DOC) of about 0.1·t or greater, such that when the glass article fracture, it breaks into a plurality of fragments having an aspect ratio of about 5 or less. In some embodiments, the glass article exhibits an equibiaxial flexural strength of about 20 kgf or greater, after being abraded with 90-grit SiC particles at a pressure of 25 psi for 5 seconds. Devices incorporating the glass articles described herein and methods for making the same are also disclosed.

Abstract: A coated glass package comprising a glass body having a Type 1 chemical durability according to USP 660, at least a class A2 base resistance or better according to ISO 695, and at least a type HGB2 hydrolytic resistance or better according to ISO 719. A lubricous coating having a thickness of ?100 microns may be positioned on at least a portion of the exterior surface of the glass body. The portion of the coated glass package with the lubricous coating comprises a coefficient of friction that is at least 20% less than an uncoated glass package and the coefficient of friction does not increase by more than 30% after undergoing a depyrogenation cycle. A horizontal compression strength of the coated glass package is at least 10% greater than an uncoated glass package and the horizontal compression strength is not reduced by more than 20% after undergoing the depyrogenation cycle.

Abstract: A coated glass container having a Type 1 chemical durability according to USP 660 (2011), a class A2 base resistance or better according to ISO 695, and a type HGB2 hydrolytic resistance or better according to ISO 719. The glass body having an interior surface and an exterior surface. A lubricous coating having a thickness of <100 microns positioned on the exterior surface. The portion of the exterior surface with the coating having a coefficient of friction that is at least 20% less than an uncoated glass container formed from the same glass composition and does not increase by more than 30% after undergoing depyrogenation at about 260° C. for 30 minutes. A horizontal compression strength of the coated glass container is at least 10% greater than an uncoated glass container formed from the same glass composition and is not reduced by more than 20% after heat treatment at about 260° C. for 30 minutes.

Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, LEVEMIR, NOVOLOG, NOVOLIN 70-30, NOVOLIN R, NOVOLIN N, NOVOLOG MIX 70-30 and NOVOLIN L.

Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient.

Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, PROCRIT (epoetin alfa), REMICADE (Infliximab) or DORIBAX (doripenem).

Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, NEUPOGEN (filgrastim), NEULASTA (pegfilgrastim), EPOGEN (epoetin alfa) or ENBREL (etanercept).

Abstract: A sterile glass pharmaceutical container or vessel such as, but not limited to, vials for holding pharmaceutical products or vaccines in a hermetic and/or sterile state. The sterile glass pharmaceutical container undergoes a strengthening process that produces compression at the surface and tension within the container wall. The strengthening process is designed such that the tension within the wall is great enough to ensure catastrophic failure of the pharmaceutical container, thus rendering the product unusable, should sterility be compromised by a through-wall crack. The tension is greater than a threshold central tension, above which catastrophic failure of the pharmaceutical container is guaranteed, thus eliminating any potential for violation of pharmaceutical integrity or sterility (such as stable cracks) in the glass packaging which are not easily identifiable in an otherwise seemingly intact pharmaceutical container.

Abstract: Disclosed herein are delamination resistant glass pharmaceutical containers which may include a glass body having a Class HGA1 hydrolytic resistance when tested according to the ISO 720:1985 testing standard. The glass body may have an interior surface and an exterior surface. The interior surface of the glass body does not comprise a boron-rich layer when the glass body is in an as-formed condition. A heat-tolerant coating may be bonded to at least a portion of the exterior surface of the glass body. The heat-tolerant coating may have a coefficient of friction of less than about 0.7 and is thermally stable at a temperature of at least 250° C. for 30 minutes.

Abstract: A method for severing a glass sheet includes preferentially heating a region of the glass sheet to form a softened region. A slit is formed in the softened region of the glass sheet to form a slit region. The slit extends at least partially into a thickness of the glass sheet. Heat is preferentially applied to the slit region of the glass sheet.

Abstract: The glass containers described herein have at least two performance attributes selected from resistance to delamination, improved strength, and increased damage resistance. In one embodiment, a glass container may include a body having an inner surface, an outer surface and a wall thickness extending between the outer surface and the inner surface. At least the inner surface of the body may have a delamination factor less than or equal to 10. A tenacious inorganic coating may be positioned around at least a portion of the outer surface of the body. The outer surface of the body with the tenacious inorganic coating may have a coefficient of friction less than or equal to 0.7.

Abstract: In embodiments, a delamination resistant glass pharmaceutical package includes a glass body formed from a Type 1 Class glass composition according to ASTM Standard E438-92, the glass body having a wall portion with an inner surface and an outer surface. The glass body may have at least a class A2 base resistance or better according to ISO 695, at least a type HGB2 hydrolytic resistance or better according to ISO 719 and Type 1 chemical durability according to USP <660>. An interior region of the glass body may extend from about 10 nm below the inner surface and have a persistent layer homogeneity. The glass body may also have a surface region extending over the inner surface and having a persistent surface homogeneity such that the glass body is resistant to delamination.

Abstract: Delamination resistant glass containers with heat-tolerant coatings are disclosed. In one embodiment, a glass container may include a glass body having an interior surface, an exterior surface and a wall thickness extending from the exterior surface to the interior surface. At least the interior surface of the glass body is delamination resistant. The glass container may further include a heat-tolerant coating positioned on at least a portion of the exterior surface of the glass body. The heat-tolerant coating may be thermally stable at temperatures greater than or equal to 260° C. for 30 minutes.

Abstract: Delamination resistant glass containers with heat-tolerant coatings are disclosed. In one embodiment, a glass container may include a glass body having an interior surface, an exterior surface and a wall thickness extending from the exterior surface to the interior surface. At least the interior surface of the glass body is delamination resistant. The glass container may further include a heat-tolerant coating positioned on at least a portion of the exterior surface of the glass body. The heat-tolerant coating may be thermally stable at temperatures greater than or equal to 260° C. for 30 minutes.

Abstract: The embodiments described herein relate to chemically and mechanically durable glass compositions and glass articles formed from the same. In an embodiment the glass composition may include from about 67 mol. % to about 80 mol. % SiO2; from about 3 mol. % to about 13 mol. % alkaline earth oxide; from about 2 mol. % to about 10 mol. % Al2O3; from about 2 mol. % to about 18 mol. % alkali oxide, wherein the alkali oxide comprises non-zero amounts of Na2O; from 0 mol. % to about 4 mol. % B2O3; and from about 0.01 mol. % to about 1 mol. % of a fining agent.